However, Benhamed et al. observed that ChREBP expression is increased in patients with NASH, 50% decreased in livers of severe insulin resistance patients, which suggested that ChREBP-mediated steatosis is not strongly associated with high insulin resistance (185), so it is uncertain whether ChREBP would be a viable target for therapeutics of NASH patients with severe insulin resistance. This evidence concerns the gene MLXIPL and steatosis.